{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:18:01Z","timestamp":1760660281911,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004854","name":"Sint Antonius Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejim.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T13:08:06Z","timestamp":1621602486000},"page":"25-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Maintenance immunosuppressive therapy in autoimmune hepatitis: To stop or not to stop, that is the question."],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-2936","authenticated-orcid":false,"given":"Mark F.J.","family":"Stolk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aad P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4034-5444","authenticated-orcid":false,"given":"Karel J.","family":"van Erpecum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.05.005_bib0001","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"Lohse","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.05.005_bib0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q J Med"},{"key":"10.1016\/j.ejim.2021.05.005_bib0003","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jhep.2017.11.020","article-title":"Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis","volume":"68","author":"Hartl","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.05.005_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"Van Gerven","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.05.005_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM198101013040102","article-title":"Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis","volume":"304","author":"Czaja","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.05.005_bib0006","first-page":"507","article-title":"Consequences of treatment withdrawal in type 1 autoimmune hepatitis","volume":"27","author":"Montano-Loza","year":"2007","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.ejim.2021.05.005_bib0007","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2021.05.005_bib0008","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.05.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2021.03.024","article-title":"Drug withdrawal in patients with autoimmune hepatitis in long-term histological remission: a prospective observational study","author":"van den Brand","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2021.05.005_bib0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.05.005_bib0011","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.05.005_bib0012","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:34:34Z","timestamp":1760607274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":12,"alternative-id":["S0953620521001564"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.05.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance immunosuppressive therapy in autoimmune hepatitis: To stop or not to stop, that is the question.","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}